<p>巴克莱在周二向客户和投资者发布的研究报告中开始覆盖 ANI 制药（NASDAQ:ANIP - 获取免费报告）的股票，Benzinga 报道。该公司对这家专业制药公司的股票设定了 “增持” 评级和 100.00 美元的目标价。巴克莱的目标价意味着该股票相较于之前的收盘价有 20.90% 的潜在上涨空间。</p>
<p>其他几位股票研究分析师也对该股票发布了报告。HC Wainwright 将 ANI 制药的目标价从 93.00 美元上调至 121.00 美元，并在 9 月 17 日的报告中给予该股票 “买入” 评级。Truist Financial 在 10 月 9 日的报告中将 ANI 制药的目标价从 77.00 美元上调至 90.00 美元，并给予该公司 “持有” 评级。Weiss Ratings 在 12 月 1 日的研究报告中重新发布了 ANI 制药的 “买入（b-）” 评级。华尔街 Zen 在 8 月 16 日的研究报告中将 ANI 制药的评级从 “买入” 上调至 “强力买入”。最后，Zacks Research 在 8 月 21 日的研究报告中将 ANI 制药的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，共识目标价为 99.38 美元。</p>
<p>获取 <strong>ANI 制药</strong> 的提醒：</p>
<p><strong>查看我们对 ANIP 的最新分析</strong></p>
<h2>ANI 制药股票表现</h2>
<p>在周二的午盘交易中，NASDAQ:ANIP 上涨 1.37 美元，达到 82.71 美元。该公司交易了 45,984 股，相比其 375,563 的平均交易量。该公司的速动比率为 2.04，流动比率为 2.58，债务与股本比率为 1.20。该股票的 50 日移动平均价格为 88.29 美元，200 日移动平均价格为 80.19 美元。该公司的市值为 18.6 亿美元，市盈率为 50.74，贝塔值为 0.48。ANI 制药的年低为 52.50 美元，年高为 99.50 美元。</p>
<p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近于 11 月 7 日发布了其财报。这家专业制药公司报告本季度每股收益为 2.04 美元，超出分析师共识预期的 1.74 美元，超出幅度为 0.30 美元。该公司本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。ANI 制药本季度的收入同比增长 53.6%。在去年同期，该公司每股收益为 1.34 美元。ANI 制药已将其 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。研究分析师预计 ANI 制药在当前财年将发布 3.86 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在其他消息中，SVP Chad Gassert 于 11 月 12 日星期三出售了 14,642 股公司的股票。该股票以 89.07 美元的平均价格出售，总交易额为 1,304,162.94 美元。出售后，这位高级副总裁直接持有 158,584 股公司的股票，价值 14,125,076.88 美元。这笔交易代表其持股减少了 8.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，SVP Krista Davis 于 9 月 19 日星期五出售了 1,000 股公司的股票。该股票以 98.04 美元的平均价格出售，总价值为 98,040.00 美元。交易后，这位高级副总裁直接持有 60,186 股公司的股票，价值约为 5,900,635.44 美元。这笔交易使其持股减少了 1.63%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了价值 2,271,691 美元的 25,579 股公司股票。内部人士持有公司股票的 12.70%。</p>
<h2>机构资金流入和流出</h2>
<p>最近几家对冲基金已增持或减持了在该公司的股份。Advisors Asset Management Inc.在第一季度购买了价值约 28,000 美元的 ANI 制药新股份。Hantz Financial Services Inc.在第三季度将其在 ANI 制药的股份增加了 202.6%。Hantz Financial Services Inc.现在拥有 354 股这家专业制药公司的股票，价值 32,000 美元，此前在该期间内增持了 237 股。Caitong International Asset Management Co. Ltd 在第二季度将其在 ANI 制药的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 现在拥有 521 股这家专业制药公司的股票，价值 34,000 美元，此前在该期间内增持了 510 股。Newbridge Financial Services Group Inc.在第二季度将其在 ANI 制药的股份增加了 200.0%。Newbridge Financial Services Group Inc.现在拥有 600 股这家专业制药公司的股票，价值 39,000 美元，此前在上个季度增持了 400 股。最后，怀俄明州在第二季度购买了价值约 50,000 美元的 ANI 制药新股份。76.05% 的股票由机构投资者和对冲基金持有。</p>
<h2>ANI 制药公司简介</h2>
<p>（获取免费报告）</p>
<p>ANI 制药公司是一家生物制药公司，在美国和加拿大开发、制造和销售品牌和仿制处方药。该公司生产口服固体剂型产品；半固体、液体和外用剂型；受控物质；以及强效产品，并进行药品的合同开发和制造。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>适合波动时期的三只沃伦·巴菲特必买股票</li>
<li>到 2026 年油价可能跌至 55 美元——这对该能源 ETF 来说是坏消息</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>在 2026 年第一季度之前购买的五只高空头头寸股票</li>
<li>十月份值得考虑购买的三只股票</li>
<li>为什么这三只汽车和工业芯片股票刚刚飙升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 ANI Pharmaceuticals 吗？</h2>
<p>在你考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ANI Pharmaceuticals 并不在名单上。</p>
<p>虽然 ANI Pharmaceuticals 目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANI制药

<p>巴克莱对 ANI 制药启动了覆盖，给予 “增持” 评级，目标价为 100 美元，暗示潜在上涨空间为 20.90%。其他分析师也发布了积极评级，普遍给予 “买入” 评级，目标价为 99.38 美元。ANI 制药报告了强劲的收益，年收入同比增长 53.6%。内部交易活动包括高级副总裁的大量股票出售。机构投资者已调整在该公司的持股比例</p>

<p>Barclays assumed coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an &#34;overweight&#34; rating and a $100.00 price target on the specialty pharmaceutical company's stock. Barclays's price target would indicate a potential upside of 20.90% from the stock's previous close.</p>
<div class="lb-trans"><p>巴克莱在周二向客户和投资者发布的研究报告中开始覆盖 ANI 制药（NASDAQ:ANIP - 获取免费报告）的股票，Benzinga 报道。该公司对这家专业制药公司的股票设定了 “增持” 评级和 100.00 美元的目标价。巴克莱的目标价意味着该股票相较于之前的收盘价有 20.90% 的潜在上涨空间。</p>
</div><p>Several other equities research analysts have also issued reports on the stock. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 17th. Truist Financial boosted their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a report on Thursday, October 9th. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of ANI Pharmaceuticals in a research note on Monday, December 1st. Wall Street Zen raised ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $99.38.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对该股票发布了报告。HC Wainwright 将 ANI 制药的目标价从 93.00 美元上调至 121.00 美元，并在 9 月 17 日的报告中给予该股票 “买入” 评级。Truist Financial 在 10 月 9 日的报告中将 ANI 制药的目标价从 77.00 美元上调至 90.00 美元，并给予该公司 “持有” 评级。Weiss Ratings 在 12 月 1 日的研究报告中重新发布了 ANI 制药的 “买入（b-）” 评级。华尔街 Zen 在 8 月 16 日的研究报告中将 ANI 制药的评级从 “买入” 上调至 “强力买入”。最后，Zacks Research 在 8 月 21 日的研究报告中将 ANI 制药的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，八位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “买入”，共识目标价为 99.38 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ANI 制药</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Analysis on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ANIP 的最新分析</strong></p>
</div><h2>ANI Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>ANI 制药股票表现</h2>
</div><p>NASDAQ:ANIP traded up $1.37 during mid-day trading on Tuesday, hitting $82.71. 45,984 shares of the company traded hands, compared to its average volume of 375,563. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock's fifty day moving average price is $88.29 and its 200-day moving average price is $80.19. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 50.74 and a beta of 0.48. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50.</p>
<div class="lb-trans"><p>在周二的午盘交易中，NASDAQ:ANIP 上涨 1.37 美元，达到 82.71 美元。该公司交易了 45,984 股，相比其 375,563 的平均交易量。该公司的速动比率为 2.04，流动比率为 2.58，债务与股本比率为 1.20。该股票的 50 日移动平均价格为 88.29 美元，200 日移动平均价格为 80.19 美元。该公司的市值为 18.6 亿美元，市盈率为 50.74，贝塔值为 0.48。ANI 制药的年低为 52.50 美元，年高为 99.50 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals's revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ANI 制药（NASDAQ:ANIP - 获取免费报告）最近于 11 月 7 日发布了其财报。这家专业制药公司报告本季度每股收益为 2.04 美元，超出分析师共识预期的 1.74 美元，超出幅度为 0.30 美元。该公司本季度的收入为 2.2781 亿美元，而分析师预期为 2.1192 亿美元。ANI 制药的净利润率为 4.91%，股本回报率为 26.73%。ANI 制药本季度的收入同比增长 53.6%。在去年同期，该公司每股收益为 1.34 美元。ANI 制药已将其 2025 财年的指导目标设定为每股收益 7.370-7.640 美元。研究分析师预计 ANI 制药在当前财年将发布 3.86 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, SVP Chad Gassert sold 14,642 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the sale, the senior vice president directly owned 158,584 shares in the company, valued at $14,125,076.88. This trade represents a 8.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the transaction, the senior vice president directly owned 60,186 shares of the company's stock, valued at approximately $5,900,635.44. The trade was a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 25,579 shares of company stock valued at $2,271,691. Insiders own 12.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Chad Gassert 于 11 月 12 日星期三出售了 14,642 股公司的股票。该股票以 89.07 美元的平均价格出售，总交易额为 1,304,162.94 美元。出售后，这位高级副总裁直接持有 158,584 股公司的股票，价值 14,125,076.88 美元。这笔交易代表其持股减少了 8.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，SVP Krista Davis 于 9 月 19 日星期五出售了 1,000 股公司的股票。该股票以 98.04 美元的平均价格出售，总价值为 98,040.00 美元。交易后，这位高级副总裁直接持有 60,186 股公司的股票，价值约为 5,900,635.44 美元。这笔交易使其持股减少了 1.63%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了价值 2,271,691 美元的 25,579 股公司股票。内部人士持有公司股票的 12.70%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 237 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. grew its position in ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after acquiring an additional 400 shares in the last quarter. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近几家对冲基金已增持或减持了在该公司的股份。Advisors Asset Management Inc.在第一季度购买了价值约 28,000 美元的 ANI 制药新股份。Hantz Financial Services Inc.在第三季度将其在 ANI 制药的股份增加了 202.6%。Hantz Financial Services Inc.现在拥有 354 股这家专业制药公司的股票，价值 32,000 美元，此前在该期间内增持了 237 股。Caitong International Asset Management Co. Ltd 在第二季度将其在 ANI 制药的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 现在拥有 521 股这家专业制药公司的股票，价值 34,000 美元，此前在该期间内增持了 510 股。Newbridge Financial Services Group Inc.在第二季度将其在 ANI 制药的股份增加了 200.0%。Newbridge Financial Services Group Inc.现在拥有 600 股这家专业制药公司的股票，价值 39,000 美元，此前在上个季度增持了 400 股。最后，怀俄明州在第二季度购买了价值约 50,000 美元的 ANI 制药新股份。76.05% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p>
<div class="lb-trans"><p>ANI 制药公司是一家生物制药公司，在美国和加拿大开发、制造和销售品牌和仿制处方药。该公司生产口服固体剂型产品；半固体、液体和外用剂型；受控物质；以及强效产品，并进行药品的合同开发和制造。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Oil Prices May Fall to $55 by 2026—Bad News for This Energy ETF</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>5 High Short-Interest Stocks to Buy Before Q1 2026</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>适合波动时期的三只沃伦·巴菲特必买股票</li>
<li>到 2026 年油价可能跌至 55 美元——这对该能源 ETF 来说是坏消息</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>在 2026 年第一季度之前购买的五只高空头头寸股票</li>
<li>十月份值得考虑购买的三只股票</li>
<li>为什么这三只汽车和工业芯片股票刚刚飙升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 ANI Pharmaceuticals 吗？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ANI Pharmaceuticals 并不在名单上。</p>
</div><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ANI Pharmaceuticals 目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

巴克莱的分析师已开始对 ANI 制药（NASDAQ:ANIP）进行研究覆盖